| Date | Time | Source | |
| 07/25/2023 | 10:33AM | GLOBE | Nymox Reports Successful New NYMOZARFEX (TM) Long-Term Prostate Cancer Treatment Clinical Trial Results
IRVINE, Calif., July 25, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation [OTC: NYMXF] (the “Company”) is pleased to announce today important new long-term clinical trial results from the Company's 146 patient NX03-0040 NYMOZARFEX (TM) U.S. study for low grade localized prostate cancer. New long-term follow-up... More...>> |
| 07/18/2023 | 10:45AM | GLOBE | Nymox Reports on U.S. Patent Issuances
IRVINE, Calif., July 18, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the “Company”) is pleased to announce the Issuances of several of its important U.S. patents for NYMOZARFEX. The Company continues to expand its patent portfolio, which is an integral part of its business. In... More...>> |
| 07/13/2023 | 10:16AM | GLOBE | Nymox Update
IRVINE, Calif., July 13, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the “Company”) is providing additional information concerning recent changes in the Company’s board of directors (the “Board”) and management, as well as additional information regarding the Company’s... More...>> |
| 07/12/2023 | 9:30AM | GLOBE | Nymox Announces Appointment Of Patrick Doody as Vice President and Member of the Board of Directors of Nymox
IRVINE, Calif., July 12, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the “Company”) is pleased to announce the appointment of Patrick Doody as Nymox Vice President, General Counsel, and Member of Nymox Board of Directors. Mr. Doody joins Nymox from Pillsbury Winthrop Shaw Pittman... More...>> |
| 07/07/2023 | 5:02PM | GLOBE | NYMOX Update
IRVINE, Calif., July 07, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation [OTC Markets – NYMXF] (the “Company”) is providing information to address requests it has received for further information concerning recent changes to the Company’s Board of Directors (“Board”) and the Company’s management... More...>> |
| 07/05/2023 | 6:11PM | GLOBE | Nymox Delisting from NASDAQ
IRVINE, Calif., July 05, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) today received a Nasdaq Hearing Delist Decision, noting that Nymox has not regained the required $1.00 share price within the 6-month extension period granted by Nasdaq, and hence the Company's shares will... More...>> |
| 05/10/2023 | 10:00AM | GLOBE | Nymox Provides Current Update
IRVINE, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to provide a mid-2nd quarter update on ongoing activities. The Company reported last month that it expects to submit an additional new submission for marketing approval of Nymozarfex, the Company's... More...>> |
| 04/03/2023 | 9:30AM | GLOBE | Nymox Provides Corporate Update
IRVINE, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to provide a current update on the Company's ongoing projects. The Company recently submitted its application for Marketing Authorization Application to the Danish authorities. The application... More...>> |
| 03/21/2023 | 10:00AM | GLOBE | Nymox Announces Appointment of Christopher R. Riley as Chief Financial Officer
IRVINE, Calif., March 21, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to announce the appointment of Christopher R. Riley as Chief Financial Officer (CFO) of Nymox. Mr. Riley is a globally experienced executive and entrepreneur with many notable successes... More...>> |
| 03/15/2023 | 9:30AM | GLOBE | Nymox Officially Granted Extension to Regain Listing Requirements
IRVINE, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) has officially been granted by NASDAQ an additional period until July 3, 2023 to regain compliance with NASDAQ listing requirements, the Company reported today. Nymox has recently submitted its Market Approval... More...>> |
| 02/15/2023 | 11:50AM | GLOBE | Nymox Announces NYMOZARFEX Marketing Application is Accepted For Review
IRVINE, Calif., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to announce that the Company's recent submission of Fexapotide Triflutate for the treatment of symptoms of benign prostate enlargement (benign prostatic hyperplasia, referred to as BPH) has been... More...>> |
| 01/06/2023 | 4:30PM | GLOBE | NYMOX Appeals Deficiency Letter
IRVINE, Calif., Jan. 06, 2023 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) reports that on January 4, 2023 the Company received a deficiency letter from The Nasdaq Stock Market (“Nasdaq”) stating that, because the Company’s common stock continues to trade at less than $1.00... More...>> |
| 12/05/2022 | 9:30AM | GLOBE | NYMOX Announces New Marketing Submission for NYMOZARFEX™ for BPH
IRVINE, Calif., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to announce today that a new formal submission has been made by the Company in Europe for Fexapotide Triflutate for the treatment of benign prostatic hyperplasia (BPH). The trademarked name for... More...>> |
| 11/25/2022 | 3:10PM | GLOBE | May 2023 Market Cap Requirement Update
IRVINE, Calif., Nov. 25, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) reports that on November 18, 2022 the Company received a deficiency letter from NASDAQ stating the Listing Rules require listed securities to maintain and minimum market value of listed securities of $35... More...>> |
| 09/13/2022 | 9:30AM | GLOBE | NYMOX Provides Current Update
IRVINE, Calif., Sept. 13, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to provide a current update on business developments. The Company has corresponded with and has met with the FDA during the past few months. The agency has provided very helpful feedback to the Company. FDA has... More...>> |
| 07/15/2022 | 9:30AM | GLOBE | NYMOX Updates Shareholders
IRVINE, Calif., July 15, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced an update to its shareholders regarding progress in the Company business activities. Nymox wishes to assure our shareholders that business plans are continuing to be developed and are on track. The Company... More...>> |
| 07/14/2022 | 12:18PM | GLOBE | NYMOX Receives Deficiency Letter from NASDAQ
IRVINE, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) reports that on July 7, 2022 the Company received a deficiency letter from NASDAQ stating that the Company is no longer in compliance with Nasdaq Listing Rule 5550(a)(2). The Nasdaq letter states that the Company will be afforded... More...>> |
| 05/23/2022 | 8:30AM | GLOBE | NYMOX Receives RTF letter from FDA
IRVINE, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) reports today that it has received a Refusal to File (“RTF”) letter from FDA on Friday May 20th at 2:48 pm EST, with regard to the Company's New Drug Application (“NDA”) for Fexapotide Triflutate. Nymox’s position... More...>> |
| 04/04/2022 | 9:45AM | GLOBE | Nymox Announces Closing of $6.4 Million Financing
IRVINE, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) (the “Company”) is pleased to announce that it has closed its $6.4 million financing announced in its filing of March 22 with institutional and accredited investors consisting of 3,878,789 common shares at a purchase price... More...>> |
| 03/18/2022 | 8:30AM | GLOBE | Nymox Announces $5 Million Registered Direct Offering
IRVINE, Calif., March 18, 2022 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced it has entered into definitive agreements with institutional and accredited investors for the purchase and sale of 3,030,304 common shares at a purchase price of $1.65 per share in a registered direct offering... More...>> |